CO2022017768A2 - Métodos para el aislamiento de linfocitos t gamma delta - Google Patents
Métodos para el aislamiento de linfocitos t gamma deltaInfo
- Publication number
- CO2022017768A2 CO2022017768A2 CONC2022/0017768A CO2022017768A CO2022017768A2 CO 2022017768 A2 CO2022017768 A2 CO 2022017768A2 CO 2022017768 A CO2022017768 A CO 2022017768A CO 2022017768 A2 CO2022017768 A2 CO 2022017768A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- cells
- lymphocytes
- isolation
- resident
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000002955 isolation Methods 0.000 title abstract 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000003394 haemopoietic effect Effects 0.000 abstract 3
- 210000004698 lymphocyte Anatomy 0.000 abstract 3
- 238000002659 cell therapy Methods 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006989.4A GB202006989D0 (en) | 2020-05-12 | 2020-05-12 | Methods for isolating gamma delta t cells |
| PCT/GB2021/051144 WO2021229226A1 (en) | 2020-05-12 | 2021-05-12 | Methods for isolating gamma delta t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017768A2 true CO2022017768A2 (es) | 2023-04-17 |
Family
ID=71134832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017768A CO2022017768A2 (es) | 2020-05-12 | 2022-12-07 | Métodos para el aislamiento de linfocitos t gamma delta |
Country Status (13)
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| UA123821C2 (uk) | 2014-06-11 | 2021-06-09 | Полібіосепт Гмбх | Композиція для експансії лімфоцитів in vitro |
| KR20240063197A (ko) * | 2015-06-09 | 2024-05-09 | 감마델타 테라퓨틱스 엘티디 | Tcr 감마 델타 양성 t 세포의 생산 방법 |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| CN108473958A (zh) * | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| JP7557367B2 (ja) * | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 細針吸引及び小生検からのtil拡大培養 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
-
2020
- 2020-05-12 GB GBGB2006989.4A patent/GB202006989D0/en not_active Ceased
-
2021
- 2021-05-12 MX MX2022014111A patent/MX2022014111A/es unknown
- 2021-05-12 CN CN202511225493.3A patent/CN121294340A/zh active Pending
- 2021-05-12 WO PCT/GB2021/051144 patent/WO2021229226A1/en not_active Ceased
- 2021-05-12 CN CN202180035561.3A patent/CN115667501B/zh active Active
- 2021-05-12 CA CA3183145A patent/CA3183145A1/en active Pending
- 2021-05-12 BR BR112022022939A patent/BR112022022939A2/pt unknown
- 2021-05-12 AU AU2021271222A patent/AU2021271222A1/en active Pending
- 2021-05-12 EP EP21727525.4A patent/EP4150055A1/en active Pending
- 2021-05-12 KR KR1020227041283A patent/KR20230010209A/ko active Pending
- 2021-05-12 IL IL298000A patent/IL298000A/en unknown
- 2021-05-12 US US17/998,766 patent/US20230227777A1/en active Pending
- 2021-05-12 JP JP2022568961A patent/JP2023525345A/ja active Pending
-
2022
- 2022-12-07 CO CONC2022/0017768A patent/CO2022017768A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667501B (zh) | 2025-09-16 |
| KR20230010209A (ko) | 2023-01-18 |
| IL298000A (en) | 2023-01-01 |
| GB202006989D0 (en) | 2020-06-24 |
| MX2022014111A (es) | 2022-12-08 |
| US20230227777A1 (en) | 2023-07-20 |
| JP2023525345A (ja) | 2023-06-15 |
| AU2021271222A1 (en) | 2023-01-05 |
| CN121294340A (zh) | 2026-01-09 |
| EP4150055A1 (en) | 2023-03-22 |
| BR112022022939A2 (pt) | 2022-12-13 |
| CA3183145A1 (en) | 2021-11-18 |
| WO2021229226A1 (en) | 2021-11-18 |
| CN115667501A (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016013747A (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| MX2019013184A (es) | Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. | |
| Reina-Ortiz et al. | Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients | |
| MX2019011570A (es) | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. | |
| Fallarini et al. | Expression of functional GPR35 in human iNKT cells | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| Alsuliman et al. | A robust, good manufacturing practice–compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy | |
| MX2019011897A (es) | Celulas efectoras inmunitarias especificas de antigenos. | |
| MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
| MX2021008022A (es) | Proteínas heterodiméricas para modular células t gamma delta. | |
| MX370018B (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2020001490A (es) | Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas. | |
| WO2013006474A3 (en) | Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 | |
| Boukouaci et al. | Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence | |
| AU2018262698A1 (en) | Expansion of gamma delta T cells, compositions, and methods of use thereof | |
| EP4470623A3 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same | |
| CR20120132A (es) | Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas | |
| BR112021019349A2 (pt) | Células-tronco preparadas altamente funcionais | |
| MX2020011263A (es) | Metodos y composiciones de agotamiento de celulas t citotoxicas. | |
| MX2021005372A (es) | Composiciones de linfocitos t con propiedades fenotípicas mejoradas. | |
| CL2010000774A1 (es) | Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso. | |
| WO2012174225A3 (en) | Isolation, expansion and use of autologous pluripotent stem cells | |
| MY166810A (en) | Isolation, expansion and characterization of precursor/stem cells from dental tissues | |
| CO2023015121A2 (es) | Nuevo método | |
| MX2022014111A (es) | Metodos para el aislamiento de linfocitos t gamma delta. |